WEKO3
アイテム
{"_buckets": {"deposit": "b272ac0a-80f4-4102-a5f2-affbf7be0d1f"}, "_deposit": {"id": "50049", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "50049"}, "status": "published"}, "_oai": {"id": "oai:tsukuba.repo.nii.ac.jp:00050049", "sets": ["2963", "1499", "7430"]}, "item_5_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2019-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "126", "bibliographicPageStart": "118", "bibliographicVolumeNumber": "8", "bibliographic_titles": [{"bibliographic_title": "CPT: Pharmacometrics \u0026 Systems Pharmacology"}]}]}, "item_5_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Plasma concentrations of dabigatran, an active principle of prodrug dabigatran etexilate (DABE), are increased by renal impairment (RI) or coadministration of a P‐glycoprotein inhibitor. Because the combined effects of drug–drug interactions and RI have not been evaluated by means of clinical studies, the decision of DABE dosing for RI patients receiving P‐glycoprotein inhibitors is empirical at its best. We conducted virtual drug–drug interactions studies between DABE and the P‐glycoprotein inhibitor verapamil in RI populations using physiologically based pharmacokinetic modeling. The developed physiologically based pharmacokinetic model for DABE and dabigatran was used to predict trough dabigatran concentrations in the presence and absence of verapamil in virtual RI populations. The population‐based physiologically based pharmacokinetic model provided the most appropriate dosing regimen of DABE for likely clinical scenarios, such as drug–drug interactions in this RI population based on available knowledge of the systems changes and in the absence of actual clinical studies.", "subitem_description_type": "Abstract"}]}, "item_5_publisher_27": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. "}]}, "item_5_relation_10": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "30659778", "subitem_relation_type_select": "PMID"}}]}, "item_5_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1002/psp4.12382", "subitem_relation_type_select": "DOI"}}]}, "item_5_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2019 The Authors CPT: Pharmacometrics \u0026 Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution- NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes."}]}, "item_5_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_5_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "21638306", "subitem_source_identifier_type": "ISSN"}]}, "item_5_subject_20": {"attribute_name": "NIIサブジェクト", "attribute_value_mlt": [{"subitem_subject": "医学", "subitem_subject_scheme": "Other"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "土岐, 浩介"}, {"creatorName": "ドキ, コウスケ", "creatorNameLang": "ja-Kana"}, {"creatorName": "DOKI, Kosuke", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "110791", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "90620881", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://nrid.nii.ac.jp/ja/nrid/1000090620881"}, {"nameIdentifier": "0000003666", "nameIdentifierScheme": "筑波大学研究者総覧", "nameIdentifierURI": "http://trios.tsukuba.ac.jp/researcher/0000003666"}]}, {"creatorNames": [{"creatorName": "本間, 真人"}, {"creatorName": "ホンマ, マサト", "creatorNameLang": "ja-Kana"}, {"creatorName": "HOMMA, Masato", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "490", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "90199589", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://nrid.nii.ac.jp/ja/nrid/1000090199589"}, {"nameIdentifier": "0000001778", "nameIdentifierScheme": "筑波大学研究者総覧", "nameIdentifierURI": "http://trios.tsukuba.ac.jp/researcher/0000001778"}]}, {"creatorNames": [{"creatorName": "Neuhoff, Sibylle", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "209369", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Rostami-Hodjegan, Amin", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "209370", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-05-20"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "CPT_8-2.pdf", "filesize": [{"value": "419.7 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_9", "mimetype": "application/pdf", "size": 419700.0, "url": {"label": "CPT_8-2", "url": "https://tsukuba.repo.nii.ac.jp/record/50049/files/CPT_8-2.pdf"}, "version_id": "f0ddcf7d-6471-4c50-9cd8-46441e124b36"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Assessing Potential Drug–Drug Interactions Between Dabigatran Etexilate and a P‐Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Assessing Potential Drug–Drug Interactions Between Dabigatran Etexilate and a P‐Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling"}]}, "item_type_id": "5", "owner": "1", "path": ["2963", "1499", "7430"], "permalink_uri": "http://hdl.handle.net/2241/00155502", "pubdate": {"attribute_name": "公開日", "attribute_value": "2019-05-20"}, "publish_date": "2019-05-20", "publish_status": "0", "recid": "50049", "relation": {}, "relation_version_is_last": true, "title": ["Assessing Potential Drug–Drug Interactions Between Dabigatran Etexilate and a P‐Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling"], "weko_shared_id": 5}
Assessing Potential Drug–Drug Interactions Between Dabigatran Etexilate and a P‐Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling
http://hdl.handle.net/2241/00155502
http://hdl.handle.net/2241/00155502cbca6a92-a877-4ec2-a1a9-b243f6857938
名前 / ファイル | ライセンス | アクション |
---|---|---|
CPT_8-2 (419.7 kB)
|
Item type | Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2019-05-20 | |||||
タイトル | ||||||
タイトル | Assessing Potential Drug–Drug Interactions Between Dabigatran Etexilate and a P‐Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源 | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | journal article | |||||
著者 |
土岐, 浩介
× 土岐, 浩介× 本間, 真人× Neuhoff, Sibylle× Rostami-Hodjegan, Amin |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Plasma concentrations of dabigatran, an active principle of prodrug dabigatran etexilate (DABE), are increased by renal impairment (RI) or coadministration of a P‐glycoprotein inhibitor. Because the combined effects of drug–drug interactions and RI have not been evaluated by means of clinical studies, the decision of DABE dosing for RI patients receiving P‐glycoprotein inhibitors is empirical at its best. We conducted virtual drug–drug interactions studies between DABE and the P‐glycoprotein inhibitor verapamil in RI populations using physiologically based pharmacokinetic modeling. The developed physiologically based pharmacokinetic model for DABE and dabigatran was used to predict trough dabigatran concentrations in the presence and absence of verapamil in virtual RI populations. The population‐based physiologically based pharmacokinetic model provided the most appropriate dosing regimen of DABE for likely clinical scenarios, such as drug–drug interactions in this RI population based on available knowledge of the systems changes and in the absence of actual clinical studies. | |||||
書誌情報 |
CPT: Pharmacometrics & Systems Pharmacology 巻 8, 号 2, p. 118-126, 発行日 2019-02 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 21638306 | |||||
PubMed番号 | ||||||
識別子タイプ | PMID | |||||
関連識別子 | 30659778 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1002/psp4.12382 | |||||
権利 | ||||||
権利情報 | © 2019 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution- NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. | |||||
著者版フラグ | ||||||
値 | publisher | |||||
出版者 | ||||||
出版者 | Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. |